Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization, combined -29% Improvement Relative Risk Hospitalization, CU-AMC -52% Hospitalization, CUIMC -5% Hospitalization, HealthVer.. 22% Hospitalization, OpenCl.. -16% Hospitalization, Optum -57% Hospitalization, VA-OMOP -47% Moreno-Martos et al. Acetaminophen for COVID-19 Prophylaxis Is prophylaxis with acetaminophen beneficial for COVID-19? Retrospective 99,890 patients in multiple countries (Jan - Jun 2020) Higher hospitalization with acetaminophen (p<0.000001) Moreno-Martos et al., Wellcome Open Research, doi:10.12688/wellcomeopenres.17403.3 Favors acetaminophen Favors control
Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe
Moreno-Martos et al., Wellcome Open Research, doi:10.12688/wellcomeopenres.17403.3
Moreno-Martos et al., Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe, Wellcome Open Research, doi:10.12688/wellcomeopenres.17403.3
Jan 2022   Source   PDF  
  All Studies   Meta
Aanlysis of prescriptions in multiple databases showing higher risk of COVID-19 hospitalization with acetaminophen use for COPD patients. Acetaminophen use was more prevalent in hospitalized patients compared to diagnosed patients (data from tables 1, 5, and S3).
risk of hospitalization, 29.3% higher, RR 1.29, p < 0.001, treatment 10,367, control 89,523, meta analysis of all databases combined.
risk of hospitalization, 51.7% higher, RR 1.52, p < 0.001, treatment 103 of 178 (57.9%), control 196 of 514 (38.1%), US CU-AMC.
risk of hospitalization, 5.1% higher, RR 1.05, p = 0.57, treatment 87 of 144 (60.4%), control 360 of 626 (57.5%), US CUIMC.
risk of hospitalization, 21.8% lower, RR 0.78, p = 0.02, treatment 64 of 319 (20.1%), control 1,585 of 6,181 (25.6%), NNT 18, US HealthVerity.
risk of hospitalization, 16.5% higher, RR 1.16, p < 0.001, treatment 2,597 of 4,983 (52.1%), control 28,320 of 63,279 (44.8%), US IQVIA OpenClaims.
risk of hospitalization, 57.0% higher, RR 1.57, p < 0.001, treatment 1,090 of 1,868 (58.4%), control 3,414 of 9,188 (37.2%), US Optum EHR.
risk of hospitalization, 47.2% higher, RR 1.47, p < 0.001, treatment 1,397 of 2,875 (48.6%), control 3,214 of 9,735 (33.0%), US VA-OMOP.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Moreno-Martos et al., 24 Jan 2022, retrospective, multiple countries, peer-reviewed, 24 authors, study period January 2020 - June 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Abstract: Wellcome Open Research 2023, 7:22 Last updated: 10 MAR 2023 RESEARCH ARTICLE Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe [version 3; peer review: 2 approved] David Moreno-Martos 1, Katia Verhamme2, Anna Ostropolets 3, Kristin Kostka4,5, Talita Duarte-Sales6, Daniel Prieto-Alhambra7, Thamir M Alshammari8, Heba Alghoul 9, Waheed-Ul-Rahman Ahmed7,10, Clair Blacketer2,11, Scott DuVall12, Lana Lai13, Michael Matheny14,15, Fredrik Nyberg 16, Jose Posada 17, Peter Rijnbeek2, Matthew Spotnitz 3, Anthony Sena2,11, Nigam Shah17, Marc Suchard 18,19, Seng Chan You 20, George Hripcsak3, Patrick Ryan3,11, Daniel Morales 1,21 1Population Health and Genomics, University of Dundee, Dundee, UK 2Medical Informatics, Erasmus MC, Rotterdam, The Netherlands 3Biomedical Informatics, Columbia University Medical Center, New York, USA 4Real World Solutions, IQVIA, Cambridge, MA, USA 5OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA 6Fundació Institut Universitari per a la recerca a l’Atenció Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), IDIAPJGol, Barcelona, Spain 7Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK 8College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia 9Faculty of Medicine, Islamic University of Gaza, Gaza, Palestinian Territory 10College of Medicine and Health, University of Exeter, Exeter, UK 11Janssen Research and Development, Janssen Research and Development, Titusville, NJ, USA 12VA Informatics and Computing Infrastructure, University of Utah, Salt Lake City, UT, USA 13Department of Medical Sciences, University of Manchester, Manchester, UK 14Geriatrics Research Education and Clinical Care Service & VINCI, Tennessee Valley Healthcare System VA, nashville, TN, USA 15Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA 16School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden 17Department of Medicine, Stanford University, Redwood City, CA, USA 18Department of Biostatistics UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA 19Department of Computational Medicine David Geffen School of Medicine at UCLA,, University of California, Los Angeles, Los Angeles, CA, USA 20Department of Preventive Medicine, Yonsei University, Seoul, South Korea 21Department of Public Health, University of Southern Denmark, Odense, Denmark v3 First published: 24 Jan 2022, 7:22 Second version: 24 Mar 2022, 7:22 Open Peer Review Approval Status Latest published: 10 Jan 2023, 7:22 1 2 version 3 Abstract Background: Characterization studies of COVID-19 patients with view Page 1 of 25 Wellcome Open Research 2023, 7:22 Last updated: 10 MAR 2023 chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a ‘diagnosed’ and ‘hospitalized’ cohort. We followed patients from COVID-19 index date to 30 days or death. We performed..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop